1. Australia Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
Actinogen Medical Limited

Actinogen Medical Limited

0.05
AUD
+0.00
(-2.08%)
0.00EPS
115.23MMarket Cap
Feb 24Next Earn
Actinogen Medical Limited
ASX:ACW
(Australian Securities Exchange)

Recent

price

0.05

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
AUD
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-0.03
-0.04
- -
- -
-0.01
-0.01
- -
-0.01
-0.01
- -
- -
-0.01
-0.01
-0.01
- -
- -
Basic EPS, GAAP
-0.03
-0.02
- -
- -
-0.01
-0.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.04
0.01
- -
0.01
0.03
0.02
0.01
0.02
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
Book Value per Share
0.04
0.01
- -
0.01
0.02
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
Tangible Book Value per Share
24
39
48
164
444
653
656
759
1,187
1,204
1,483
1,812
1,902
2,174
2,980
3,332
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
-1,786.94
-2,152.49
- -
-2,958.88
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-1
-2
- -
- -
-5
-4
-3
-6
-10
-5
-4
-9
-11
-13
-15
-15
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-1,262.12
-2,965.66
- -
-2,201.11
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
1
- -
- -
1
10
7
5
13
12
7
14
19
11
18
16
20
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
1
- -
- -
1
15
12
9
17
16
11
17
22
13
20
18
21
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
-66.94
-219.53
-60.83
-62.61
-65.56
-26.44
-29.69
-46.81
-60.07
-40.15
-27.62
-48.46
-61.18
-78.81
-77.47
-77.46
Return on Common Equity (%)

Capital Structure

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

AUD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.49%
8.55%
16.57%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
26.36%
38.89%
4.4%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Semi-annual Earnings Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.01
2025
- -
- -
- -
2026
- -
- -
- -

Semi-annual Dividends Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
Actinogen Medical Limited is an Australian biotechnology firm dedicated to developing treatments for a range of neurological and neuropsychiatric conditions linked to imbalanced brain cortisol levels. The company is advancing Xanamem (emestedastat), an oral small molecule that selectively inhibits the 11β-HSD1 enzyme to modulate cortisol within the brain. Xanamem is currently undergoing a pivotal Phase 2b/3 clinical trial for Alzheimer's disease in Australia and the United States, targeting mild to moderate forms of the condition. Further, Xanamem has shown positive Phase 2a results for cognitive impairment in Major Depressive Disorder and is also being explored for its potential in Fragile X Syndrome. Established in 1999, the company adopted its current name in November 2015 and operates from Sydney, Australia.

Company News

Company News APIChatGPT

  • proactiveinvestors.com

    Actinogen Medical enters ‘database lock' to process XanaMIA' data and confirm findings

  • proactiveinvestors.com

    Actinogen Medical closes September quarter with XanaMIA readout in sight

  • proactiveinvestors.com

    Actinogen's Xanamem trial hits key milestone ahead of results - ICYMI

  • proactiveinvestors.com

    Actinogen Medical completes final XanaMIA patient visit; November Alzheimer's trial results on track

  • proactiveinvestors.com

    Dow slips, Nasdaq edges lower as August ends in green

  • proactiveinvestors.com

    Nvidia's $12.9bn Hugging Face swoop is really about filling the cloud capacity it has underwritten

  • proactiveinvestors.com

    UBS says bond market relief from falling yields will not offset deeper structural pressures

  • proactiveinvestors.com

    Riot Platforms $9.1B AI deal fuels speculation around Anthropic IPO

  • proactiveinvestors.com

    Traders see little chance of Hormuz shipping recovery by end of August

  • proactiveinvestors.com

    Hikma jumps 10% as brokers point to profit beat and undemanding rating

  • proactiveinvestors.com

    Actinogen Medical outlines scientific case for Xanamem in Alzheimer’s disease ahead of pivotal trial results

  • proactiveinvestors.com

    The Small Cap Watch: Healthcare, critical minerals and gold explorers advance projects

  • proactiveinvestors.com

    Actinogen Medical advances pivotal XanaMIA trial towards November readout - ICYMI

  • proactiveinvestors.com

    Novo Resources expands Wyloo silver targets - ICYMI

  • proactiveinvestors.com

    Horizon Gold details A$1.31B Gum Creek NPV - ICYMI

  • proactiveinvestors.com

    Resolution Minerals secures second FAST-41 status - ICYMI

  • proactiveinvestors.com

    Actinogen Medical’s Xanamem shows meaningful antidepressant activity in Phase 2 trial